BARDA and Luminex Corporation are collaborating on rapid development of the diagnostic test called the NxTAG CoV Extended Panel for COVID-19.
The test uses RNA to detect the presence of the SARS-COV-2 virus and is intended for use with the company’s IVD MAGPIX® molecular diagnostic system. This high-throughput option will add test capacity in the U.S. on equipment currently installed in U.S. healthcare facilities. Test results are available in less than four hours.
Luminex already has begun shipping of the NxTAG® CoV Extended Panel under Research Use Only (RUO) in North America, Europe and the Far East and has received FDA Emergency Use Authorization on March 27, 2020.
In this cost-sharing partnership, BARDA will contribute expertise and approximately 36 percent of the funding necessary to develop the test. Luminex will provide the remaining development costs.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
ABOUT THE COMPANY
The following information is provided by Luminex and does not indicate endorsement by the federal government of the company or its products.
At Luminex, Austin, TX, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit luminexcorp.com.